Guardant Health faces $245M royalty liability for patent infringement, adding to financial strain

What happened

A Delaware federal judge finalized a $245.2 million royalty judgment against Guardant Health for willful infringement of TwinStrand Biosciences and University of Washington Duplex Sequencing patents, cementing a November 2023 jury verdict. This liability adds to Guardant's financial burdens, as the company already operates with negative free cash flow and a substantial convertible debt load, with only ~$1.3 billion in cash on hand. The payment, if made in full, would reduce cash reserves by nearly one-fifth and could force management to seek additional financing or further delay its path to free cash flow breakeven. While the core oncology franchise remains profitable, this legal setback challenges the company's ability to fund its costly Shield screening expansion without equity or debt issuance. Investors should treat this as a material adverse event that underscores the operational and financial risks already highlighted in the bear case for Guardant Health.

Implication

This ruling validates the bear scenario outlined in the DeepValue master report, which already flagged limited margin of safety and the potential need for capital raises. The $245 million payment directly reduces cash reserves and could push free cash flow breakeven further out if the company must reallocate funds from growth investments. Management may choose to fund the liability through additional convertible debt or ATM equity issuance, diluting existing shareholders and pressuring the stock. Furthermore, the willful infringement finding may invite additional litigation costs or royalty obligations on other patents, raising long-term legal risk. Investors should reduce or avoid exposure until there is clarity on how Guardant will manage this cash outflow and whether it signals broader intellectual property vulnerabilities.

Thesis delta

The thesis previously leaned toward trimming or avoiding new positions given crowded expectations and limited upside. This news crystallizes a specific financial liability that was not fully priced in, increasing the probability of downside to the bear case implied value of $75. The conviction in a potential sell rating strengthens from 4.0 to a higher level, and the attractive entry point may need to be lowered to reflect the reduced cash position and higher financing risk.